INSERM U-987, CHU Ambroise Paré, APHP, Université Versailles Saint-Quentin, Boulogne-Billancourt, France.
Pain. 2018 Mar;159(3):576-582. doi: 10.1097/j.pain.0000000000001136.
Neuropathic pain represents a highly unmet medical need because most of the available treatments have a modest efficacy or dose-limiting side effects. Hence, novel therapeutic perspectives are warranted. Many compounds acting on new pain targets are in preclinical or early clinical development. Only few clinical trials have suggested their clinical relevance in neuropathic pain. This concerns in particular NaV1.7 antagonists and angiotensin type II inhibitors. Another type of emerging drug therapy in neuropathic pain is represented by drugs largely used for other indications, such as botulinum toxin A and the antiepileptic oxcarbazepine, which have recently found to be effective in peripheral neuropathic pain. Emerging nondrug medical therapy with promising results in neuropathic pain also encompasses noninvasive brain neurostimulation techniques, such as repetitive transcranial magnetic stimulation and transcranial direct electrical stimulation. In this article, we review emerging medical treatments for neuropathic pain that are clinically available or with promising results from clinical trials.
神经病理性疼痛是一种高度未满足的医疗需求，因为大多数可用的治疗方法疗效有限或具有剂量限制的副作用。因此，需要新的治疗方法。许多针对新的疼痛靶点的化合物正在进行临床前或早期临床开发。只有少数临床试验表明它们在神经病理性疼痛中的临床相关性。这特别涉及到 NaV1.7 拮抗剂和血管紧张素 II 抑制剂。神经病理性疼痛中另一种新兴的药物治疗类型是代表了其他适应证广泛使用的药物，例如肉毒杆菌毒素 A 和抗癫痫药奥卡西平，它们最近被发现对周围神经病理性疼痛有效。在神经病理性疼痛方面具有有前景的结果的新兴非药物医学治疗方法还包括有前途的非侵入性脑神经刺激技术，例如重复经颅磁刺激和经颅直流电刺激。在本文中，我们综述了临床上可获得或具有临床试验有前景结果的神经病理性疼痛的新兴医学治疗方法。
